INSYS Therapeutics Implements Leadership Changes

PHOENIX, April 15, 2019 — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company.Continue reading

New techniques may detect CTE in brains of living former NFL players

Arizona researchers are playing a key role in the search for new ways to identify CTE before death. In a study released online in the New England Journal of Medicine, a cross-national team, including local researchers from Arizona State University, Banner Alzheimer’s Institute, the Mayo Clinic College of Medicine, and Boston University have brought us a step closer to diagnosing CTE in living, former NFL players.Continue reading